>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Puromycin dihydrochloride

Puromycin dihydrochloride 嘌呤霉素二盐酸盐; CL13900 dihydrochloride

Puromycin dihydrochloride (CL13900 dihydrochloride) 是一种氨基核苷类抗生素，抑制蛋白合成 (protein synthesis)。

货号：
TK0604
规格：

1mg

5mg

10mg

50mg
价格：
￥0.00

产品参数

CAS No.	58-58-2
生物活性	Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis.
分子式	C22H29N7O5.2HCl
分子量	544.43
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : ≥ 77.5 mg/mL (142.35 mM) H2O : 50 mg/mL (91.84 mM; Need ultrasonic and warming)
体外研究	Puromycin blocks protein synthesis after aminoacyl-sRNA formation, and at the same time it leads to the accumulation of small peptides. Both of these effects appear to be due to the splitting of ribosome-bound peptidyl-sRNA,4 which results in release of incomplete peptide chains.. Puromycin, an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains. Puromycin has two modes of inhibitory action. The first is by acting as an acceptor substrate which attacks peptidyl-tRNA in the P site to form a nascent peptide. The second is by competing with aminoacyl-tRNA for binding to the A' site. When used in minimal amounts, puromycin incorporation in neosynthesized proteins reflects directly the rate of mRNA translation in vitro. Puromycin immunodetection is an advantageous alternative to radioactive amino acid labeling. It allows the direct evaluation of translation activity in single cells by immunofluorescence microscopy and in heterogenous populations of cells by fluorescenceactivated cell sorting.
文献	•Adv Funct Mater. 2019, 1808556. •Hepatology. 2021 Apr;73(4):1327-1345. •J Hematol Oncol. 2021 Jul 10;14(1):109. •Autophagy. 2021 Mar 25;1-19. •Mol Cancer. 2019 Aug 22;18(1):127. •Nat Commun. 2019 Dec 2;10(1):5492. •Bioact Mater. 12 November 2021. •Theranostics. 2021 Mar 5;11(10):5045-5060. •Theranostics. 2020 May 16;10(14):6483-6499. •J Exp Clin Cancer Res. 2021 Nov 25;40(1):373. •J Exp Clin Cancer Res. 2016 Nov 7;35(1):173. •Oncogene. 2021 Nov 29. •EMBO Rep. 2021 Jun 23;e52205. •Cancer Lett. 2021 Jul 30;518:266-277. •Cancer Lett. 2021 Apr 29;S0304-3835(21)00180-4. •Cancer Lett. 2020 Nov 1;492:162-173. •Cell Death Dis. 2021 Oct 14;12(10):944. •Cell Death Dis. 2021 Sep 9;12(9):842. •Cell Death Dis. 2020 Dec 2;11(12):1032. •Cell Death Dis. 2019 Nov 21;10(12):879. •Biomed Pharmacother. 2020 Jan;121:109578. •Front Oncol. 21 April 2021. •Acta Pharmacol Sin. 2021 Jan;42(1):108-114. •Biochem Pharmacol. 2020 Apr;174:113776. •Biochem Pharmacol. 2017 Mar 15;128:12-25. •Cancer Cell Int. 2019 Jul 24;19:192. •Aging. 2021 Jun 8;13(11):14892-14909. •Aging. 2020 Sep 14;12(17):17122-17136. •Int J Oncol. 2020 Jul;57(1):161-170. •Stem Cells Int. 2020 Aug 29;2020:8860185. •J Cell Mol Med. 2019 Feb;23(2):954-966. •Cell Death Discov. 2021 Aug 30;7(1):226. •Cell Death Discov. 2021 May 1;7(1):89. •J Biol Chem. 2021 Feb 10;296:100413. •J Biol Chem. 2021 Jan 8;100276. •Cancer Med. 2019 Oct;8(13):5903-5915. •BMC Cancer. 2018 Feb 13;18(1):182. •Cell Signal. 2020, 109878. •Cell Signal. 2019 Mar 5;58:119-130. •Toxicol Appl Pharmacol. 2019 Sep 1;378:114625. •Oncotargets Ther. 2020 Sep 30;13:9701-9719. •Onco Targets Ther. 2019 Jan 25;12:835-848. •Am J Transl Res. 2021 May 15;13(5):4360-4375. •Am J Transl Res. 2021 Apr 15;13(4):2331-2349. •Cancer Manag Res. 2021 Nov 30;13:8915-8928. •Cancer Manag Res. 11 November 2021. •Oncol Rep. 2020 Dec 9. •Biochem Biophys Res Commun. 1 January 2022, Pages 34-41. •Biochem Biophys Res Commun. 2021 Oct 5;580:48-55. •Clin Transl Oncol. 2021 Apr 7. •Anal Biochem. 2021 Aug 29;114357. •Exp Mol Pathol. 2021 Oct 5;104704. •PLoS One. 2017 Oct 10;12(10):e0185565. •R Soc Open Sci. 2018 Aug 29;5(8):172376. •Evid Based Complement Alternat Med. 2019 Mar 24;2019:1635837. •Cancer Invest. 2021 Mar 8;1-34. •Research Square Preprint. 2022 Jan. •Research Square Preprint. 2021 Nov. •Research Square Preprint. 2021 Aug. •SSRN. 2021 Jun.
纯度及产品资料	98%

推荐产品